VAN SCOYOC ASSOCIATES for UNIVERSITY OF PENNSYLVANIA SCHOOL OF MEDICINE
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Public Law 111-148, Patient Protection and Affordable Care Act (PPACA), Medicare Reimbursement; and Comparative Effectiveness Research. Monitor implementation of PPA Study on GME issues. Drug Safety issues Clinical Trial Reform issues FDA extramural research issues. Partnership for Patient Program issues. Graduate Medical Education funding issues. HOPPS Regulation, Proton theory issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KEVIN PATRICK KELLY | — |
| KEVIN F KELLY | — |
Veterans VET
No lobbying activity.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KEVIN F KELLY | — |
| KEVIN PATRICK KELLY | — |
Budget/Appropriations BUD
S.2375/H.R.5973, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2013, FDA funding initiatives. Public Law 111-148, Patient Protection and Affordable Care Act, Medicare Reimbursement; Comparative Effectiveness Research; Geographic Variation; and issues related to Academic Health Centers S.3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, FY2013, Agency for Healthcare Research and Quality, Centers for Education and Research on Therapeutics (CERTS Center), NIH funding. Graduate Medical Education funding issues. Public Law 112-74, Consolidated Appropriations Act, FY2012, Agency for Healthcare Research and Quality, Centers for Education and Research on Therapeutics (CERTS Center), NIH funding. Public Law 112-55, Consolidated and Further Continuing Appropriations Act, FY2012, FDA funding initiatives. H.J.Res.117, Continuing Appropriations Resolution, FY2013, Sequestration issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KEVIN F KELLY | — |
| KEVIN PATRICK KELLY | — |
Medicare/Medicaid MMM
Physician payment issues. Non-profit hospital regulations and oversight. Comparative effectiveness research.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KEVIN PATRICK KELLY | — |
| KEVIN F KELLY | — |
Pharmacy PHA
FDA funding initiatives; Critical Path Partnership. S.2375/H.R.5973, Agriculture,Rural Development,Food and Drug Administration,and Related Agencies Appropriations Act, FY2013 Public Law 112-10, Department of Defense and Full-Year Continuing Appropriations Act, FY2011 Public Law 112-55, Consolidated and Further Continuing Appropriations Act, FY2012 Monitor Prescription Drug User Fee Act (PDUFA)
| Lobbyist | Covered position, as disclosed |
|---|---|
| KEVIN F KELLY | — |
| KEVIN PATRICK KELLY | — |
Medical/Disease Research/Clinical Labs MED
Public Law 111-148, Patient Protection and Affordable Care Act, Medicare Reimbursement; Comparative Effectiveness Research; and Federal Medical Assistance Payments (FMAP) issues. Federal Medical Assistance Payments (FMAP) legislation and tax extenders.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KEVIN F KELLY | — |
| KEVIN PATRICK KELLY | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.